Celastrol alleviates SGLT2 inhibitor-induced diabetic hyperketonemia by inhibiting hepatic ketogenesis

Authors:

Abstract
SGLT2 inhibitor (SGLT2i)-induced diabetic hyperketonemia is a life-threatening acute complication of diabetes. While Celastrol has been reported to exert beneficial effects on obesity; its potential role in ketogenesis remains unclear. In this study, Celastrol administration significantly attenuates the fasting-induced elevation of blood β-hydroxybutyrate. Moreover, a 7-day course of Celastrol (1 mg/kg/day) leads to reductions in body weight and fat mass. Mechanistically, Celastrol specifically downregulates HMGCS2 expression and suppressess hepatic ketogenesis through inhibiting PPARα expression in the short term (≤ 2 days). However, after prolonged treatment for 7 days, Celastrol modulates both PPARαand serum free fatty acids (FFAs) levels. Furthermore, anti-ketogenic effect of Celastrol is abolished in Ppar α□ / □ mice. Importantly, Celastrol effectively ameliorates SGLT2i-induced hyperketonemia. In summary, Celastrol curbs hepatic ketone overproduction in a PPARα-dependent manner, indicating its protective potential against SGLT2i-induced hyperketonemia.
Funding Information
  • Natural Science Foundation of Beijing Municipality (7242094)
  • National Key Research and Development Program of China (2022YFC2504003)
  • National Key Research and Development Program of China (2022YFC2504002)
  • Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences

This publication has 43 references indexed in Scilit: